摘要
补充和替代疗法(CAM)被定义为目前没有被认定为传统医疗实践的治疗方法。当用作传统疗法的补充时被称为“补充”,用作传统疗法的替代时被称为“替代”。CAM包括许多不同的实践,例如印度韦达养生学、针灸或传统中药(TCM)、植物疗法、顺势疗法、益生菌和膳食补充剂。尽管已有一些有利证据存在证明以上大多数的治疗方法,,但这些疗法的疗效和安全性仍没有被设计良好的科学研究所证实。然而,IBD患者的中的补充和替代疗法的使用很常见,医生也经常面对如何使用他们的问题。因为大多数报道的研究包含方法学难题,医生通常难以充分告知患者。不过,CAM的广泛使用需要被认可。一些疗法因在IBD患者中发挥合理的生物学效应而值得进一步调查。IBD中的对照实验能保证CAM的疗效和安全。本文旨在简要概述当前在IBD患者中使用的各种补充和替代疗法。
关键词: 印度韦达养生学,补充疗法,炎症性肠道疾病,磷脂酰胆碱,益生菌,传统中药
Current Drug Targets
Title:Complementary Therapies in Inflammatory Bowel Diseases
Volume: 15 Issue: 11
Author(s): Philip Esters and Axel Dignass
Affiliation:
关键词: 印度韦达养生学,补充疗法,炎症性肠道疾病,磷脂酰胆碱,益生菌,传统中药
摘要: Complementary and alternative therapies (CAM) are defined as therapies that are presently not considered part of conventional medical practice. They are termed “complementary” when used in addition to conventional therapies and termed “alternative” when used instead of conventional therapies. CAM includes many different practices, for example Ayurveda, acupuncture or traditional Chinese medicine (TCM), phytotherapy, homeopathy, probiotics and dietary supplements. While some evidence of benefit exists regarding some therapies, for most of these therapeutic approaches, the therapeutic efficacy and safety have not been proven in well-designed scientific studies. However, the use of complementary and alternative medicine among IBD patients is common, and physicians are frequently confronted with questions about their use. As most of the reported studies contain methodological problems, it is often difficult for physicians to inform their patients adequately. Nevertheless, the widespread use of CAM needs to be recognized. Some of these agents exert plausible biological effects in IBD patients and warrant further investigation. Controlled trials in IBD are warranted to show therapeutic benefits and safety of CAM. This review aims to give a brief overview on the current use of various complementary and alternative treatment options in IBD patients.
Export Options
About this article
Cite this article as:
Esters Philip and Dignass Axel, Complementary Therapies in Inflammatory Bowel Diseases, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140903112802
DOI https://dx.doi.org/10.2174/1389450115666140903112802 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toll-Like Receptors in Skin Infections and Inflammatory Diseases
Infectious Disorders - Drug Targets Hallmarks in the Therapeutic Approach of Aortic Aneurysms: The Main Contributors
Current Pharmaceutical Design Coronary Artery Bypass Graft in HIV-Infected Patients: A Multicenter Case Control Study
Current HIV Research Preparation, Crystallization and Preliminary X-Ray Analysis of Threonine Synthase from Streptococcus mutans
Protein & Peptide Letters In Vitro Synergistic Action of Certain Combinations of Gentamicin and Essential Oils
Current Medicinal Chemistry Pneumonia Due to Methicilin-Resistant Staphylococcus aureus (MRSA): A Review
Current Respiratory Medicine Reviews Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design Novel Strategies for Combating Pathogenic Biofilms Using Plant Products and Microbial Antibiosis
Current Pharmaceutical Biotechnology Bergenin - A Biologically Active Scaffold: Nanotechnological Perspectives
Current Topics in Medicinal Chemistry Production of Fibrinolytic Protease from a Halobacterium <i>Bacillus licheniformis</i> VITLMS Isolated from Marine Sponges of Rameshwaram Coast, India
Current Bioactive Compounds Caenorhabditis elegans: A Model for Studying Human Pathogen Biology
Recent Patents on Biotechnology HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design Editorial: Bioengineering, Clinical and Therapeutical Trends in Transcatheter Aortic Valve Implantation
Current Pharmaceutical Design In silico Analysis of Toxins of Staphylococcus aureus for Validating Putative Drug Targets
Infectious Disorders - Drug Targets The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design Riboswitches as Potential Targets for the Development of Anti-Biofilm Drugs
Current Topics in Medicinal Chemistry Antibacterial Combination of Oleoresin from Copaifera multijuga Hayne and Biogenic Silver Nanoparticles Towards Streptococcus agalactiae
Current Pharmaceutical Biotechnology